Hedge Funds Were Net Buyers of Financials, Healthcare for Week: Goldman Sachs
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Why Recursion Is Getting Love as an AI and Drug Discovery Top Pick
Inflation cooling solidifies the expectation of Fed rate cuts! Will this industry become the new darling of Wall Street?
The SPDR S&P Biotech ETF (XBI) has achieved five consecutive gains, with a cumulative increase of nearly 8% in 5 days.
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
IShares Genomics Immunology and Healthcare ETF Declares Semi-annual Distribution of $0.1114